US Officials Hope To Identify Correlates of Protection For COVID-19 Vaccines Shortly
Executive Summary
Accelerated approval might soon be in the cards for COVID-19 vaccines if an immune correlate of protection can be identified through ongoing work by FDA and NIH. Meanwhile, to speed more vaccines to Americans, FDA is trying to help ramp up manufacturing. Sanofi is set to commence a Phase IIb trial with an active comparator.
You may also be interested in...
US FDA Sets Immunogenicity Bar High For Changes To COVID-19 Vaccines
Modified vaccines targeted at new SARS-CoV-2 variants must generate immune response rates not more than 10% below those of the original vaccine, agency says in one of a suite of guidances on medical product development to address variants.
US FDA v. COVID Mutants: Multi-Factorial Assessments Will Determine When Product EUAs Need To Change
Acting Commissioner Janet Woodcock offers hints as to the content of upcoming guidance on how emerging virus variants may impact vaccine and therapeutic development. US may need multivalent vaccine and multiple boosters.
COVID-19 Vaccines: Pediatric Effectiveness Bridging Not Dependent Upon Immune Correlates
Ability to bridge from adult effectiveness data to children in the absence of an identified correlate of protection could be affected by proposed dosing regimen and expected similarity in pediatric response, US FDA official says.